Pfizer Price to Sales Ratio 2010-2023 | PFE

Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of April 24, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pfizer P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-24 26.27 2.56
2023-12-31 28.36 $10.26 2.76
2023-09-30 32.23 $12.00 2.69
2023-06-30 35.24 $13.62 2.59
2023-03-31 38.77 $16.24 2.39
2022-12-31 48.24 $17.51 2.76
2022-09-30 40.85 $17.45 2.34
2022-06-30 48.56 $17.69 2.75
2022-03-31 47.57 $16.16 2.94
2021-12-31 53.86 $14.27 3.78
2021-09-30 38.88 $12.12 3.21
2021-06-30 35.08 $9.75 3.60
2021-03-31 32.14 $8.17 3.93
2020-12-31 32.30 $7.41 4.36
2020-09-30 30.22 $5.70 5.30
2020-06-30 26.67 $6.12 4.36
2020-03-31 26.35 $6.70 3.93
2019-12-31 31.31 $7.19 4.35
2019-09-30 28.43 $7.06 4.03
2019-06-30 33.96 $7.03 4.83
2019-03-31 33.00 $6.96 4.74
2018-12-31 33.63 $6.81 4.94
2018-09-30 33.69 $8.88 3.80
2018-06-30 27.50 $8.83 3.11
2018-03-31 26.65 $8.71 3.06
2017-12-31 26.94 $8.79 3.07
2017-09-30 26.32 $8.65 3.04
2017-06-30 24.52 $8.61 2.85
2016-12-31 23.25 $8.56 2.72
2016-09-30 24.01 $8.59 2.79
2016-06-30 24.75 $8.41 2.94
2016-03-31 20.64 $8.17 2.53
2015-12-31 22.26 $7.81 2.85
2015-09-30 21.48 $7.60 2.83
2015-06-30 22.75 $7.60 2.99
2015-03-31 23.41 $7.68 3.05
2014-12-31 20.78 $7.71 2.70
2014-09-30 19.56 $7.63 2.56
2014-06-30 19.46 $7.60 2.56
2014-03-31 20.87 $7.44 2.80
2013-12-31 19.74 $7.40 2.67
2013-09-30 18.37 $7.14 2.57
2013-06-30 17.76 $6.97 2.55
2013-03-31 18.15 $7.00 2.59
2012-12-31 15.64 $7.25 2.16
2012-09-30 15.35 $6.99 2.20
2012-06-30 14.08 $7.39 1.90
2012-03-31 13.73 $7.62 1.80
2011-12-31 12.99 $7.71 1.68
2011-09-30 10.51 $8.17 1.29
2011-06-30 12.11 $8.03 1.51
2011-03-31 11.82 $8.08 1.46
2010-12-31 10.08 $8.07 1.25
2010-09-30 9.79 $8.40 1.17
2010-06-30 8.04 $8.13 0.99
2010-03-31 9.57 $7.63 1.25
2009-12-31 10.05 $7.20 1.40
2009-09-30 9.06 $7.05 1.28
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $149.038B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77